About this item:
201 Views | 171 Downloads
Author Notes:
Correspondence: Jonathan Li, MD, MMSc, Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, 65 Landsdowne Street, Rm 421, Cambridge, MA 02139 (jli@bwh.harvard.edu)
V.C.M. has received research funding from Gilead.
B.O.T. has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau and has received grant funding to his institution from ViiV/ GlaxoSmithKline (GSK).
C.B.M. has received a consulting fee from NU.
C.J.F. has received payment for service on the Clinical Care Options speakers bureau and grant funding to his institution from ViiV, Gilead, Merck, Janssen, and Pfizer.
C.A.B. has received payment for GSK board membership and Infectious Diseases Society of America board membership, speakers bureau, and travel and is an associate editor for Clinical Infectious Diseases; she has received grant funding to her institution from Gilead.
T.W. has served as a paid consultant for ViiV/GSK and has received grant funding to his institution from ViiV/GSK, Gilead, and Bristol-Myers Squibb; his spouse holds stock options at Johnson & Johnson.
S.L.K. has received grant funding to her institution from Gilead.
E.P.A. reported nonfinancial support from GSK/ViiV.
J.Z.L. has served as a paid consultant and received grant funding from Gilead and Merck.
P.E.S. has served as a paid consultant to Gilead, Abbvie, Merck, Janssen, ViiV/GSK, and Bristol-Myers Squibb and has received grant funding to his institution from Gilead and ViiV/GSK.
All other authors have nothing to disclose.
Subjects:
Research Funding:
This work was supported by an investigator-sponsored study grant from ViiV HealthCare to Northwestern University (NU).
V.C.M., C.J.F., C.A.B., T.W., S.L.K., J.C., J.Z.L., and P.E.S. have received grant funding for this study to their institutions through NU from ViiV/GSK.
V.C.M. has received funding from the Emory CFAR (P30AI050409).
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Immunology
- Infectious Diseases
No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial
Tools:
Abstract:
Copyright information:
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
